Could Local Application of Hypoxia Inducible Factor 1-alpha Enhancer Deferoxamine Be Promising for Preventing of Medication-Related Osteonecrosis of the Jaw?

Basit Öğe Kaydı
dc.contributor.authorYalçın-Ülker, Gül Merve
dc.contributor.authorGünbatan, Murat
dc.contributor.authorDuygu, Gonca
dc.contributor.authorSoluk-Tekkesin, Merva
dc.contributor.authorÖzçakir-Tomruk, Ceyda
dc.date.accessioned2023-05-06T17:20:47Z
dc.date.available2023-05-06T17:20:47Z
dc.date.issued2023
dc.departmentFakülteler, Diş Hekimliği Fakültesi, Klinik Bilimler Bölümü
dc.description.abstractThis experimental study investigates the prophylactic effect of deferoxamine (DFO) on medication-related osteonecrosis of the jaw (MRONJ). Thirty-six female Sprague Dawley rats received zoledronic acid (ZA) for eight weeks to create an osteonecrosis model. DFO was locally applied into the extraction sockets with gelatin sponge (GS) carriers to prevent MRONJ. The specimens were histopathologically and histomorphometrically evaluated. Hypoxia-inducible factor 1-alpha (HIF-1 alpha) protein levels in the extraction sockets were quantified. New bone formation rate differed significantly between groups (p = 0.005). Newly formed bone ratios in the extraction sockets did not differ significantly between the control group and the GS (p = 1), GS/DFO (p = 0.749), ZA (p = 0.105), ZA-GS (p = 0.474), and ZA-GS/DFO (p = 1) groups. While newly formed bone rates were higher in the ZA-GS and ZA-GS/DFO groups than in the ZA group, the differences were not significant. HIF-1 alpha levels differed significantly between groups (p < 0.001) and were significantly higher in the DFO and ZA-GS/DFO groups than in the control group (p = 0.001 and p = 0.004, respectively). While HIF-1 alpha levels were higher in the ZA-GS/DFO group than in the ZA group, the difference was not significant. While HIF-1 alpha protein levels and new bone formation rate were elevated in the DFO-treated group, the effect was not significant. Further large-scale studies are needed to understand DFO's preventative effects on MRONJ and the role of HIF-1 alpha in MRONJ pathogenesis.
dc.identifier.doi10.3390/biomedicines11030758
dc.identifier.issn2227-9059
dc.identifier.issue3en_US
dc.identifier.pmid36979736
dc.identifier.scopus2-s2.0-85151530313
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.3390/biomedicines11030758
dc.identifier.urihttps://hdl.handle.net/20.500.11776/11931
dc.identifier.volume11
dc.identifier.wosWOS:000954259100001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorDuygu, Gonca
dc.language.isoen
dc.publisherMdpi
dc.relation.ispartofBiomedicines
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectbisphosphonate
dc.subjectdeferoxamine
dc.subjecthypoxia-inducible factor 1-alpha
dc.subjectmedication-related osteonecrosis of the jaw
dc.subjecttooth extraction
dc.subjectBisphosphonate-Related Osteonecrosis
dc.subjectPlatelet-Rich Fibrin
dc.subjectGene-Expression
dc.subjectGrowth-Factors
dc.subjectAngiogenesis
dc.subjectPamidronate
dc.subjectRegeneration
dc.subjectZoledronate
dc.subjectAlendronate
dc.subjectFracture
dc.titleCould Local Application of Hypoxia Inducible Factor 1-alpha Enhancer Deferoxamine Be Promising for Preventing of Medication-Related Osteonecrosis of the Jaw?
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
11931.pdf
Boyut:
2.57 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Diş Hekimliği Fakültesi Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu